#United States #Eye Care #Ponte Vedra #Qlosi #Orasis Pharmaceuticals

Orasis Pharmaceuticals Doubles Down on Eye Care Initiatives

Orasis Pharmaceuticals has reaffirmed its commitment to eye care professionals by rolling out two new offerings that aim to improve patient access to their innovative eye drop treatment, Qlosi® (pilocarpine hydrochloride ophthalmic solution) 0.4%. This initiative comes as refill rates for the product have remarkably reached 49%, signifying a significant accomplishment when compared to traditional retail pharmacy metrics for dry eye prescription therapies.

New Offerings to Support Eye Care Professionals

The first initiative is a First Fill Free program in collaboration with pharmacy partner BlinkRx. This initiative allows patients to receive their first prescription of Qlosi at no cost, followed by standard pricing for subsequent refills. Furthermore, in-office dispensing options are now available in certain states, allowing eye care professionals (ECPs) to provide immediate access to the treatment during patient visits. These efforts align with Orasis' strategy of centering their offerings around the expertise of ECPs rather than a direct-to-consumer telehealth model.

Elad Kedar, the CEO of Orasis Pharmaceuticals, expressed the company's goal: "Our aim has always been to enable patients to see clearly at close range without the need for reading glasses." The success of Qlosi can partly be attributed to the support of eye care professionals, who are now seeing refill rates that are approximately double those typically recorded in retail settings, indicating patients are experiencing substantial improvements in their near vision and are committed to continuing their treatment.

Positive Feedback from Eye Care Professionals

The positive response from professionals in the field highlights the coalition between practical treatment options and patient preferences. Dr. David Rouse, an optometrist and esteemed member of the optometry community, remarked on the benefits of this initiative: "The option for a no-cost first fill significantly reduces barriers for patients initiating treatment. Now, I can provide Qlosi directly from my office, making it easier for the right patients to leave with their treatment in hand after their visit." This feedback not only underscores the efficacy of Qlosi as witnessed in clinical trial settings but also demonstrates the seamless integration of these new offerings within professional practices.

The Significance of Refills and Continuous Treatment

Since its launch in the U.S. in April 2025, Qlosi has gained noteworthy traction among ECPs, with reports showing a refill rate of 49%. This figure is pivotal, as it signifies a heightened adherence among patients to treatment regimens, a critical factor in managing presbyopia, which affects nearly 128 million people in the U.S. alone. The ability of Qlosi to aid patients in regaining near visual acuity without compromising their distance vision is a breakthrough that presents a welcome alternative for individuals confronted with age-related blurry near vision.

Real-world experiences continue to echo the safety and efficacy data gathered during pivotal Phase 3 trials, with no significant adverse reports such as retinal tears or detachments linked to Qlosi. This safety profile furthers the commitment of Orasis to patient well-being, enhancing the overall treatment experience for those grappling with presbyopia.

Understanding Presbyopia and Eye Health

Presbyopia, a condition that generally begins to affect individuals after the age of 40, occurs as the eye's crystalline lens loses flexibility. Nearly two billion people worldwide are impacted, rendering daily tasks like reading exceptionally challenging. The gradual progression of presbyopia means that without effective treatment, individuals often find themselves reaching for reading glasses.

Orasis Pharmaceuticals, through its innovative approach centered on the needs of ECPs and patients alike, is reshaping the dialogue around presbyopia care. The introduction of Qlosi as a non-invasive and effective solution reflects an important advancement in the field of ophthalmic pharmaceuticals.

As Orasis continues to explore ways to enhance their product accessibility and patient education, the partnership with BlinkRx stands as a testament to their dedication to improving patient outcomes and fostering a supportive environment for eye care professionals.

For more detailed information about the First Fill Free program or about prescribing Qlosi, visit qlosiecp.com/how-to-prescribe and to place orders for in-office dispensing, check qlosiecp.com/in-office. The commitment to eye care from Orasis Pharmaceuticals shines a light on the pathway forward for effective, accessible treatments in the realm of vision health.